Oligosaccharide-Modified GLP-1 Peptides for Blood Sugar Control
Solution Overview
Problem
Current GLP-1 peptides have a short half-life in the blood, limiting their therapeutic potential due to rapid clearance, and modifications such as PEGylation can lead to adverse reactions and antibody formation, while existing oligosaccharide chain additions are not uniform and lack stability.
Innovation Solution
Development of an oligosaccharide chain added GLP-1 peptide with specific amino acid substitutions at positions 18, 20, 22, 26, 30, 34, or 36, using oligosaccharide chains like disialo or hyaluronic acid, linked directly or via a linker, to enhance stability and activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If PEGylation is used to prolong half-life, then stability and duration of action are improved, but adverse reactions and antibody formation occur
Solution Approach 1:
The invention changes the chemical nature of the conjugate from synthetic PEG to natural oligosaccharide chains, altering the parameter of biocompatibility while maintaining the duration-extending function. The oligosaccharide chains are metabolizable unlike PEG, eliminating accumulation and adverse reactions while still prolonging half-life to at least 1 hour
Solution Approach 2:
The invention creates a composite structure by conjugating oligosaccharide chains to the GLP-1 peptide backbone, combining the therapeutic activity of GLP-1 with the stability-enhancing properties of oligosaccharide moieties, achieving both prolonged duration and reduced immunogenicity
2Duration of action of moving object
If oligosaccharide chains are added to prolong half-life, then stability is improved, but uniformity and manufacturing precision are insufficient
Solution Approach 1:
The invention applies oligosaccharide chains at specific local positions on the GLP-1 peptide (amino acid positions 6, 11, 16, 21, 26, or 31), ensuring consistent and controlled modification sites that improve manufacturing uniformity while maintaining the stability benefits
Solution Approach 2:
The oligosaccharide chains are introduced as discrete, defined segments with specific structures (such as disialo chains or hyaluronic acid oligomers) rather than heterogeneous polymers, enabling precise control over the conjugate's physical and chemical properties for consistent manufacturing
3Duration of action of moving object
If big hyaluronic acid molecules are used to prolong half-life, then stability is improved, but structural uniformity and manufacturing precision deteriorate
Solution Approach 1:
Instead of using large, heterogeneous hyaluronic acid molecules, the invention segments the hyaluronic acid into smaller, defined oligomer units with controlled molecular weights and structures, enabling precise manufacturing while maintaining the stability-prolonging effect
Solution Approach 2:
The invention changes the molecular weight parameter of the hyaluronic acid component from high molecular weight (200 KDa) to controlled oligomer sizes, improving solubility, uniformity, and manufacturing precision while retaining the ability to prolong half-life through controlled degradation
Data Source
AI summary
Oligosaccharide chain added GLP-1 peptides are more stable in blood and more active in controlling blood-sugar levels than GLP-1 peptides without added oligosaccharides. Oligosaccharide chain added GLP-1 peptides having GLP-1 activity include at least one or at least two amino acids each substituted with an oligosaccharide chain added amino acid in GLP-1; a peptide having the amino acid sequence of GLP-1 with deletion, substitution or addition of one or several amino acids; or a GLP-1 analog. Oligosaccharide chain added GLP-1 peptides with at least one amino acid substituted with an oligosaccharide chain added amino acid include an oligosaccharide chain with oligo hyaluronic acid. Oligosaccharide chain added amino acids include oligosaccharide chains attached to amino acids via linkers.



